| Company Name: |
BOC Sciences |
| Tel: |
16314854226; +8616314854226 |
| Email: |
inquiry@bocsci.com |
CCB02 manufacturers
- CCB02
-
- $70.00
-
2026-07-15
- CAS:2100864-57-9
- Purity: 99.98%
- Supply Ability: 10g
- CCB02
-
- $70.00
-
2026-07-15
- CAS:2100864-57-9
- Purity: 99.98%
- Supply Ability: 10g
|
| Product Name: | CCB02 | | Synonyms: | CCB02;Benzo[b][1,6]naphthyridine-4-carbonitrile, 3-methoxy-;CCB-02,CCB02 | | CAS: | 2100864-57-9 | | MF: | C14H9N3O | | MW: | 235.24 | | EINECS: | | | Product Categories: | | | Mol File: | 2100864-57-9.mol |  |
| | CCB02 Chemical Properties |
| Boiling point | 467.2±25.0 °C(Predicted) | | density | 1.33±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : 25 mg/mL (106.27 mM) | | pka | 2.53±0.30(Predicted) | | form | Solid | | color | Light yellow to yellow |
| | CCB02 Usage And Synthesis |
| Description | CCB02 is a selective CPAP-tubulin interaction inhibitor, binding to tubulin and competing for the CPAP binding site of β-tubulin, with an IC50 of 689 nM, and shows potent anti-tumor activity. CCB02 shows no inhibition on the cell cycle- and centrosome-related kinases, or the phosphorylation status of Aurora A, Plk1, Plk2, CDK2, and CHK1[1]. CCB02 is a selective CPAP-tubulin interaction inhibitor, binding to tubulin and competing for the CPAP binding site of β-tubulin, with an IC50 of 689 nM. CCB02 perturbs CPAP PN2-3-tubulin interaction with an IC50 of 0.441 μM in a PN2-3 CPAP-GST pull-down assay[1].CCB02 shows no inhibition on the cell cycle- and centrosome-related kinases, or the phosphorylation status of Aurora A, Plk1, Plk2, CDK2, and CHK1[1].CCB02 inhibits the proliferation of cancer cells with extra centrosomes, IC50s are 0.86-2.9 μM. CCB02 activates spindle assembly checkpoint, induces PCM proteins recruitment to centrosomes, and enhances microtubule nucleation activities of centrosomes[1]. CCB02 (30 mg/kg, p.o. daily) shows potent anti-tumor effect in nude mice bearing subcutaneous human lung (H1975T790M cells) tumor xenografts. CCB02 also suppresses MDA-MB-231 cell migration and cuases multipolar mitosis in mouse xenografts[1]. | | Uses | CCB02 is a selective CPAP-tubulin interaction inhibitor, binding to tubulin and competing for the CPAP binding site of β-tubulin, with an IC50 of 689 nM, and shows potent anti-tumor activity. CCB02 shows no inhibition on the cell cycle- and centrosome-related kinases, or the phosphorylation status of Aurora A, Plk1, Plk2, CDK2, and CHK1[1]. | | in vivo | CCB02 (30 mg/kg, p.o. daily for 24 days) shows potent anti-tumor effect in nude mice bearing subcutaneous human lung (H1975T790M cells) tumor xenografts[1].
CCB02 also suppresses MDA-MB-231 cell migration and cuases multipolar mitosis in mouse xenografts[1]. | Animal Model: | Nude mice bearing subcutaneous human lung (H1975T790M) tumor xenografts[1] | | Dosage: | 30 mg/kg | | Administration: | P.O. daily for 24 days | | Result: | Significantly decreased the tumor volume on day 24. |
| | References | [1]. Mariappan A, et al. Inhibition of CPAP-tubulin interaction prevents proliferation of centrosome-amplified cancer cells. EMBO J. 2019 Jan 15;38(2). pii: e99876. |
| | CCB02 Preparation Products And Raw materials |
|